-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
-
Summary
-
Alnylam Pharmaceuticals, Inc. quarterly/annual Revenues history and growth rate from Q3 2020 to Q4 2022.
- Alnylam Pharmaceuticals, Inc. Revenues for the quarter ending December 31, 2022 was $335M, a 29.6% increase year-over-year.
- Alnylam Pharmaceuticals, Inc. Revenues for the twelve months ending December 31, 2022 was $1.04B, a 22.9% increase year-over-year.
- Alnylam Pharmaceuticals, Inc. annual Revenues for 2022 was $1.04B, a 22.9% increase from 2021.
- Alnylam Pharmaceuticals, Inc. annual Revenues for 2021 was $844M, a 71.3% increase from 2020.
- Alnylam Pharmaceuticals, Inc. annual Revenues for 2020 was $493M, a 124% increase from 2019.
Revenues, Trailing 12 Months (USD)
Revenues, Quarterly (USD)
Revenues, YoY Quarterly Growth (%)